# Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI

Study · id `cardio:ct-nct03252665` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03252665](<https://clinicaltrials.gov/study/NCT03252665>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03252665

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

## Technical summary

Registry record NCT03252665. Randomized; single masking; primary purpose treatment. Start 2017-09-01 (anticipated); primary completion 2019-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT03252665, source copy `cardio:ctgov-nct03252665-2017-08-17`, retrieved 2026-10-26)
- Planned start: 2017-09-01 (anticipated) (ClinicalTrials.gov record NCT03252665, source copy `cardio:ctgov-nct03252665-2017-08-17`, retrieved 2026-10-26)
- Primary completion: 2019-06-30 (anticipated) (ClinicalTrials.gov record NCT03252665, source copy `cardio:ctgov-nct03252665-2017-08-17`, retrieved 2026-10-26)
- Completion: 2019-06-30 (anticipated) (ClinicalTrials.gov record NCT03252665, source copy `cardio:ctgov-nct03252665-2017-08-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03252665, source copy `cardio:ctgov-nct03252665-2017-08-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03252665-2017-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
- Condition: ST Segment Elevation Myocardial Infarction
- Intervention (Drug): Alprostadil
- Intervention (Drug): Nicorandil
- Intervention (Drug): Nitroglycerin
- Lead sponsor: RenJi Hospital
- Lead sponsor class: OTHER
- Collaborator: Shanghai 10th People's Hospital
- Collaborator class: OTHER
- Collaborator: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Collaborator class: OTHER
- Collaborator: Shanghai 6th People's Hospital
- Collaborator class: OTHER
- Collaborator: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Collaborator class: OTHER
- Collaborator: Ruijin Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: RenJi Hospital (`cardio:org-renji-hospital`)
- Registry lists this organization as a collaborator: Shanghai 10th People's Hospital (`cardio:org-shanghai-10th-people-s-hospital`)
- Registry lists this organization as a collaborator: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-general-hospital-shanghai-jiao-tong-university-237209`)
- Registry lists this organization as a collaborator: Shanghai 6th People's Hospital (`cardio:org-shanghai-6th-people-s-hospital`)
- Registry lists this organization as a collaborator: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (`cardio:org-xinhua-hospital-shanghai-jiao-tong-university-school-of-9039af`)
- Registry lists this organization as a collaborator: Ruijin Hospital (`cardio:org-ruijin-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial (`cardio:pubmed-33847683`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 966d88534005f626a112fe49f157d321d39ced2b04751634c05c2a346adf362d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
